Full Medtronic Results Offer Little Reason For Optimism On Renal Denervation
This article was originally published in The Gray Sheet
Executive Summary
Renal denervation did not have a significant effect on systolic blood pressure in the SYMPLICITY HTN-3 trial, the first major sham-controlled trial of renal denervation for drug-resistant hypertension. The trial’s sponsor, Medtronic, had previously announced that it missed its primary endpoint but full results of the study were presented for the first time at the ACC meeting in Washington, DC on March 29.
You may also be interested in...
Renal Denervation Story Not Over Yet Despite SYMPLICITY HTN-3 Disappointment
Even though the first major sham-controlled trial showed no benefit for renal denervation in treating hypertension, statements provided by companies developing the technology suggest they are not giving up on it yet.
Future Of Renal Denervation On Trial At ACC 2014 This Weekend
The full results of Medtronic’s SYMPLICITY HTN-3 trial, to be presented at the American College of Cardiology Scientific Sessions on March 29, could determine the fate of the renal denervation devices under development by several major companies for drug-resistant hypertension.
Covidien Quits Renal Denervation Race; Others Stick It Out, For Now
A Covidien executive said in an interview that the firm’s decision to halt development of its OneShot renal denervation system was made prior to Medtronic’s recent announcement that its Symplicity device missed its endpoint. Covidien cites slower-than-expected development of the renal denervation market.